ETR:SRT - Sartorius Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started €98.20 -3.30 (-3.25 %) (As of 12/14/2018 04:00 PM ET)Previous Close€101.50Today's Range€98.20 - €102.0052-Week RangeN/AVolume1,147 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry. It provides filtration and purification, sterile filtration, virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, integrity testing, and OEM membranes; process analyzers, process control tools, microbiology products, and chemometric software; single-use bioprocess bags, containers, mixing systems, aseptic transfer systems, freeze and thaw systems, aseptic sampling and bottle closure systems, and tubing dis-/connectors; media USP and buffers DSP; bioreactors/fermentors; and FlexAct, a system that enables to custom-configure single-use solutions for entire biomanufacturing steps. The Lab Products & Services division provides laboratory instruments, such as lab balances, pipettes, and laboratory water purification systems; and consumables, including laboratory filters and pipette tips. Its products include OEM weigh cells, mass comparators and metrology, weights/weight sets, and paint mixing solutions; microbiology products and moisture analyzers; lab water systems; pipette tips and pipette calibration; bioreactors/fermentors and centrifuges; and filtration, ultrafiltration, membrane chromatography products, virus purification kits, diagnostic membranes and arrays, and blotting membranes, as well as aseptic bottle closure systems. The company also offers instrument, validation, and training services. It serves biopharmaceutical and pharmaceutical, public research institutes, and chemical and food sectors. The company was founded in 1870 and is headquartered in Goettingen, Germany. Receive SRT News and Ratings via Email Sign-up to receive the latest news and ratings for SRT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ETR Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolETR:SRT Previous Symbol CUSIPN/A Webwww.sartorius.com Phone49 551 308 0 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Sartorius (ETR:SRT) Frequently Asked Questions What is Sartorius' stock symbol? Sartorius trades on the ETR under the ticker symbol "SRT." What price target have analysts set for SRT? 8 Wall Street analysts have issued 12-month price objectives for Sartorius' shares. Their forecasts range from €93.00 to €142.00. On average, they expect Sartorius' stock price to reach €114.88 in the next twelve months. This suggests a possible upside of 17.0% from the stock's current price. View Analyst Price Targets for Sartorius. What is the consensus analysts' recommendation for Sartorius? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius in the last year. There are currently 4 sell ratings and 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sartorius. Has Sartorius been receiving favorable news coverage? Media headlines about SRT stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sartorius earned a news impact score of -1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the immediate future. Who are some of Sartorius' key competitors? Some companies that are related to Sartorius include 3D Signatures (DXD), BioNano Genomics (BNGOU), Cambridge Cognition (COG), Carl Data Solutions (CRL), Carl Zeiss Meditec (AFX), Co-Diagnostics (CODX), Deepmatter Group (DMTR), EPIGENOMICS AG/S (EPGNY), Eternity Healthcare (ETAH), Genedrive (GDR), GeneNews (GEN), Imaging Dynamics (IDL), LED Medical Diagnostics (LMD), Lexagene (LXG) and MaxCyte (MXCT). Who are Sartorius' key executives? Sartorius' management team includes the folowing people: Dr. Joachim Kreuzburg, Chairman of Exec. Board & CEO (Age 53)Mr. Rainer Lehmann, CFO & Member of Exec. Board (Age 42)Mr. Reinhard Vogt, Head of Bioprocess Solutions Division & Member of the Exec. Board (Age 63)Ms. Petra Kirchhoff, VP of Corp. Communications & Investor Relations and Member of Supervisory Board (Age 49)Mr. Osacr-Werner Reif, Chief Technology Officer What is Sartorius' stock price today? One share of SRT stock can currently be purchased for approximately €98.20. What is Sartorius' official website? The official website for Sartorius is http://www.sartorius.com. How can I contact Sartorius? The company can be reached via phone at 49 551 308 0. MarketBeat Community Rating for Sartorius (ETR SRT)Community Ranking: 1.9 out of 5 ()Outperform Votes: 20 (Vote Outperform)Underperform Votes: 33 (Vote Underperform)Total Votes: 53MarketBeat's community ratings are surveys of what our community members think about Sartorius and other stocks. Vote "Outperform" if you believe SRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?